We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

MorphoSys Provides an Update on its Proprietary Development Portfolio

News   Sep 10, 2015

 
MorphoSys Provides an Update on its Proprietary Development Portfolio
 
 
 

RELATED ARTICLES

Sickle Cell Drug IMR-687 Shows Promise in Clinical Trial

News

An investigational drug for the treatment of sickle cell disease shows early promise in Phase 2a clinical trial. The orally administered drug, given to adult patients with sickle cell disease, is demonstrating tolerability and the ability to impact both red and white blood cell biomarkers of the disease.

READ MORE

A New Role for Cohesin Protein in Tumors and Rare Diseases?

News

Cohesin mutations have been identified in some types of cancer and in rare diseases referred to as cohesinopathies. Now, scientsits describe new functions of cohesin in mouse embryonic stem cells that might help understand and address the causes of these disorders.

READ MORE

Patent Issued for Osteoarthritis Gene Therapy Product

News

A potentially disease-modifying therapy for osteoarthritis has reached a key milestone now that a U.S. patent has been issued for FX201, a gene-therapy product candidate based on work led by Baylor College of Medicine researchers.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE